A New Day For Knight
Knight has failed to build a meaningful business or create long-term shareholder value, despite tremendous opportunity and resources. The current Board and CEO are conflicted and entrenched, attacking shareholders rather than acknowledging and addressing the Company’s poor execution and performance.
Medison has developed a comprehensive plan to help Knight become a growing and profitable Canadian-based pharmaceutical company, but new directors are needed to ensure the implementation of this plan. In addition to current director Meir Jakobsohn, Medison has nominated five independent, experienced leaders from the pharmaceutical industry who will oversee Knight without conflict or compromise.
Enter your info below to stay up-to-date.